TR200103545T2 - Dolastatin 15-türevleri. - Google Patents

Dolastatin 15-türevleri.

Info

Publication number
TR200103545T2
TR200103545T2 TR2001/03545T TR200103545T TR200103545T2 TR 200103545 T2 TR200103545 T2 TR 200103545T2 TR 2001/03545 T TR2001/03545 T TR 2001/03545T TR 200103545 T TR200103545 T TR 200103545T TR 200103545 T2 TR200103545 T2 TR 200103545T2
Authority
TR
Turkey
Prior art keywords
group
monovalent
mammal
amino
formula
Prior art date
Application number
TR2001/03545T
Other languages
English (en)
Turkish (tr)
Inventor
Janssen Bernd
Barlozzari Teresa
Haupt Andreas
Zierke Thomas
Kling Andreas
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of TR200103545T2 publication Critical patent/TR200103545T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/26—Preparation of nitrogen-containing carbohydrates
    • C12P19/28—N-glycosides
    • C12P19/30—Nucleotides
    • C12P19/34—Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR2001/03545T 1997-07-18 1998-07-07 Dolastatin 15-türevleri. TR200103545T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives

Publications (1)

Publication Number Publication Date
TR200103545T2 true TR200103545T2 (tr) 2002-06-21

Family

ID=25406130

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2001/03545T TR200103545T2 (tr) 1997-07-18 1998-07-07 Dolastatin 15-türevleri.
TR2000/00132T TR200000132T2 (tr) 1997-07-18 1998-07-07 Dolastatin 15 türevleri

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2000/00132T TR200000132T2 (tr) 1997-07-18 1998-07-07 Dolastatin 15 türevleri

Country Status (32)

Country Link
US (6) US6143721A (enExample)
EP (1) EP0991658B1 (enExample)
JP (4) JP4508413B2 (enExample)
KR (1) KR100579748B1 (enExample)
CN (1) CN1268636C (enExample)
AR (1) AR018501A1 (enExample)
AT (1) ATE314387T1 (enExample)
AU (1) AU750120B2 (enExample)
BG (1) BG65212B1 (enExample)
BR (1) BR9810911A (enExample)
CA (1) CA2296036C (enExample)
CO (1) CO4990967A1 (enExample)
CY (1) CY1107047T1 (enExample)
CZ (1) CZ303045B6 (enExample)
DE (1) DE69832982T2 (enExample)
DK (1) DK0991658T3 (enExample)
ES (1) ES2258819T3 (enExample)
HR (1) HRP980397A2 (enExample)
HU (1) HU228996B1 (enExample)
ID (1) ID24669A (enExample)
IL (1) IL133784A (enExample)
MY (1) MY135057A (enExample)
NO (1) NO326827B1 (enExample)
NZ (1) NZ502296A (enExample)
PL (1) PL197884B1 (enExample)
PT (1) PT991658E (enExample)
RU (1) RU2195462C2 (enExample)
SK (1) SK286581B6 (enExample)
TR (2) TR200103545T2 (enExample)
TW (1) TW533217B (enExample)
WO (1) WO1999003879A1 (enExample)
ZA (1) ZA986358B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6686336B2 (en) 2000-02-08 2004-02-03 Federal Government As Represented By The Department Of Veterans Affaires N-terminal D(-)-penicillamine peptides as aldehyde sequestration agents
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
RU2342399C2 (ru) * 2002-03-22 2008-12-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Производные гемиастерлина и их применение при лечении рака
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
DK1545613T3 (da) * 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
PL2489364T3 (pl) 2003-11-06 2015-06-30 Seattle Genetics Inc Związki monometylowaliny zdolne do sprzęgania do przeciwciał
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
PE20140625A1 (es) 2007-07-16 2014-05-29 Genentech Inc ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS
PL2176296T3 (pl) 2007-07-16 2012-07-31 Genentech Inc Przeciwciała anty-CD79B i immunokoniugaty i sposoby stosowania
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
PT2247620T (pt) 2008-01-31 2016-08-23 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
BR112012014899A2 (pt) 2009-12-18 2017-03-14 Idenix Pharmaceuticals Inc composto, composição farmacêutica, método para tratar ou prevenir uma infecção por vírus de hepatite c em um sujeito, método para tratar , prevenir ou melhorar um ou mais sintomas de uma doença hepática ou distúrbio associado a uma infecção por vírus de hepatite c em um sujeito, método para inibir a replicação de um vírus em um hospedeiro, método para inibir a replicação de um vírus
RU2573994C2 (ru) 2010-02-10 2016-01-27 Иммьюноджен, Инк Антитела против cd20 и их применение
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Ｉａｐ ｂｉｒ 도메인 결합 화합물
US10131682B2 (en) 2012-11-24 2018-11-20 Hangzhou Dac Biotech Co., Ltd. Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
CN114262344A (zh) 2014-02-28 2022-04-01 杭州多禧生物科技有限公司 带电荷链接体及其在共轭反应上的应用
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
CN108449940B (zh) 2015-07-12 2021-06-08 杭州多禧生物科技有限公司 与细胞结合分子的共轭偶联的桥连接体
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
CN116143678A (zh) 2016-11-14 2023-05-23 杭州多禧生物科技有限公司 偶联连接体，含有此连接体的细胞结合分子-药物偶联物及其制备和应用
MX2024002571A (es) 2021-09-03 2024-03-20 Toray Industries Composicion farmaceutica para tratamiento y/o prevencion de cancer.
KR20240095442A (ko) 2021-11-03 2024-06-25 항저우 디에이씨 바이오테크 씨오, 엘티디 항체의 특이적 접합

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
SG87056A1 (en) * 1991-08-09 2002-03-19 Teikoku Hormone Mfg Co Ltd Novel tetrapeptide derivative
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
US5448045A (en) * 1992-02-26 1995-09-05 Clark; Paul C. System for protecting computers via intelligent tokens or smart cards
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
HUT71398A (en) * 1992-05-20 1995-11-28 Basf Ag Derivatives of dolastatin
NZ258882A (en) * 1992-12-16 1997-06-24 Basf Ag Antineoplastic peptides and compositions thereof
US5554993A (en) * 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) * 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) * 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
CA2287379C (en) * 1997-01-10 2005-10-04 Silicon Gaming-Nevada Method and apparatus for providing authenticated, secure on-line communication between remote locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) * 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) * 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) * 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Also Published As

Publication number Publication date
JP5047935B2 (ja) 2012-10-10
US20030153505A1 (en) 2003-08-14
KR100579748B1 (ko) 2006-05-15
CZ303045B6 (cs) 2012-03-07
CN1268636C (zh) 2006-08-09
US20130046077A1 (en) 2013-02-21
CZ2000176A3 (en) 2001-06-13
HUP0004234A2 (hu) 2001-05-28
ES2258819T3 (es) 2006-09-01
US6143721A (en) 2000-11-07
TW533217B (en) 2003-05-21
HRP980397A2 (en) 1999-04-30
JP4508413B2 (ja) 2010-07-21
KR20010021998A (ko) 2001-03-15
EP0991658A1 (en) 2000-04-12
JP2009137967A (ja) 2009-06-25
JP5122429B2 (ja) 2013-01-16
IL133784A0 (en) 2001-04-30
AR018501A1 (es) 2001-11-28
DE69832982D1 (de) 2006-02-02
CN1264388A (zh) 2000-08-23
DE69832982T2 (de) 2006-08-24
HK1029125A1 (en) 2001-03-23
ZA986358B (en) 2000-01-17
AU750120B2 (en) 2002-07-11
CA2296036A1 (en) 1999-01-28
WO1999003879A1 (en) 1999-01-28
CO4990967A1 (es) 2000-12-26
JP2009137968A (ja) 2009-06-25
US8163698B2 (en) 2012-04-24
RU2195462C2 (ru) 2002-12-27
AU8475898A (en) 1999-02-10
SK286581B6 (sk) 2009-01-07
US20100099843A1 (en) 2010-04-22
BG65212B1 (bg) 2007-07-31
PL197884B1 (pl) 2008-05-30
JP2012211164A (ja) 2012-11-01
NO20000231L (no) 2000-01-17
PL338144A1 (en) 2000-09-25
US6458765B1 (en) 2002-10-01
ID24669A (id) 2000-07-27
BG104089A (en) 2000-12-29
CA2296036C (en) 2007-05-01
CY1107047T1 (el) 2012-09-26
HU228996B1 (hu) 2013-07-29
JP2001515010A (ja) 2001-09-18
EP0991658B1 (en) 2005-12-28
US20060270606A1 (en) 2006-11-30
DK0991658T3 (da) 2006-05-15
NO326827B1 (no) 2009-02-23
SK187999A3 (en) 2000-09-12
US7662786B2 (en) 2010-02-16
BR9810911A (pt) 2000-08-01
IL133784A (en) 2005-09-25
MY135057A (en) 2008-01-31
TR200000132T2 (tr) 2000-05-22
HUP0004234A3 (en) 2001-08-28
ATE314387T1 (de) 2006-01-15
NZ502296A (en) 2002-02-01
NO20000231D0 (no) 2000-01-17
US7084110B2 (en) 2006-08-01
PT991658E (pt) 2006-05-31

Similar Documents

Publication Publication Date Title
TR200103545T2 (tr) Dolastatin 15-türevleri.
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
PT1005445E (pt) Derivados de n-alcanoilfenilalanina
NO971889D0 (no) Forbindelser og sammensetninger for levering av aktive midler
CY1113969T1 (el) Ανευ-αλβουμινης συνταγοποιησεις παραγοντα viii
PT2327719E (pt) Expressão híbrida e em série de proteínas de neisseria
WO2002048183A3 (en) Compositions of peptide crystals
DK1442058T3 (da) Peptider der er effektive til behandling af tumorer og andre tilstande der kræver fjernelse eller destruktion af celler
ATE348883T1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
TR200200843T2 (tr) İşemi'nin Tedavisi için olan bileşikler
DE50112802D1 (de) Peptide, deren herstellung und verwendung zur bindung von immunglobulinen
DE69840603D1 (de) Alpha-ketoamidhaltige multikatalytische protease inhibitoren
TR200201244T2 (tr) Göz kurumasının iyileştirilmesi için Lipoksin A4 ve analogları
NO20031671L (no) Dioksolananaloger for forbedret intercellulaer avlevering
PT1149910E (pt) Composicao farmaceutica contra os tumores e as infeccoes por papilomavirus
ATE286139T1 (de) Replikationskompetente anti-tumor vektoren
NO955067L (no) FVII/TF peptider
BRPI0410655A (pt) composição farmacêutica, método de tratar ou prevenir uma infecção pelo vìrus da raiva em um indivìduo em necessidade deste tratamento, vetor de expressão de rhabdovìrus recombinante, célula hospedeira de mamìfero, método de produzir uma anticorpo recombinante humano neutralizante do vìrus da raiva em uma célula de mamìfero, e, uso de uma combinação
AU2001274421A1 (en) Compositions based on aminoacids, suitable for the treatment of heart failure
EP1389101A4 (en) ANTITUMOR COMPOSITION CONTAINING A TOLUENE SULFONAMIDE AND METHOD OF USE
WO2001043761A3 (en) Methods for treating and preventing damage to mucosal tissue
FR2781230B1 (fr) Derives de peptides utilisables comme inhibiteur selectif du site n-terminal de l'enzyme de conversion de l'angiotensine humaine
ATE263574T1 (de) Verwendung von canp-inhibitoren in pharmazeutischen zubereitungen
DE60301387D1 (en) Phosphinsäure pseudo-peptidderivate
IT1276453B1 (it) Vaccino/composizioni terapautica di helycobacter pylori, loro preparazione ed impiego.